Urologic Oncology-Seminars and Original Investigations

Papers
(The H4-Index of Urologic Oncology-Seminars and Original Investigations is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Urinary biomarkers in bladder cancer: A review of the current landscape and future directions91
Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database71
Mutations in renal cell carcinoma49
Reconsideration of pelvic floor muscle training to prevent and treat incontinence after radical prostatectomy42
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor40
Diet and lifestyle considerations for patients with prostate cancer34
The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients34
Papillary renal cell carcinoma: Review32
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy32
Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis29
Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer29
Investigating the association between the urinary microbiome and bladder cancer: An exploratory study29
Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review28
Ethnic disparities among men with prostate cancer undergoing germline testing28
Non-muscle-invasive bladder cancer: An overview of potential new treatment options28
Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer27
Role of miRNAs in prostate cancer: Do we really know everything?27
Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?26
Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review26
Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer25
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis25
Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer24
Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?24
Mutational landscape of non-muscle-invasive bladder cancer23
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma23
Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?23
0.41306185722351